Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 102 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 102 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Dromokaiteio Psychiatric Hospital of Athens

2. Health Center of Skiathos, General Hospital of Volos, Volos

3. Mitera Maternity Hospital of Athens, Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Farmer J.A., Gotto A.M.,Jr: Dyslipidemia and other risk factors for coronary artery disease. In: (Braunwold E., ed.) Heart Disease: A Textbook of Cardiovascular Medicine. Pp. 1126-1160, 5th ed., WB Saunders, Philadelphia, 1997

3. Neaton J.D., Wentworth D.: Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152: 56-64 (1992)

4. LaRosa J.C., Hunninghake D., Bush D., et al.: The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Commissioned by the Task Force on Cholesterol Issues, American Heart Association. Circulation 81(1721): 33 (1990)

5. Ridker P.M., Cushatan M., Stampfer M.J., Tracy R.P., Hennekens C.H.: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336: 973-979 (1996)

6. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 285: 2486-2497 (2001)

7. Vaughan C.S., Murphy M.B., Buckley B.M.: Statins do more than just lower cholesterol. Lancet 348: 1079-1082 (1996)

8. Rosenson R.S., Tangney C.C.: Antiatherothrombotic property of statins. Implication for cardiovascular event reduction. JAMA 279: 1643-1650 (1998)

9. The controversy over homocysteine and cardiovascular risk factors. Atherosclerosis 141: 315-319 (1998) (Medline)

10. Mc Cullyks:  Homocysteine and vascular disease. Nat. Med. 2: 386-389 (1996) (Medline)

11. Libby P.: Imflammation in atherosclerosis. Nature 420: 868-874 (2002)

12. Davigno J.: Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(Suppl.): III39-III43 (2004)

13. Vam Lente F.: Markets of inflammation as predictors in cardiovascular disease. Clin. Chim. Act. 293: 31-53 (2000)

14. Weikert B., et al.: B Vitamin plasma levels and the risk of ischemic stroke and Transient Ischemic Attack in a German Cohor. Stroke 38: 2912-2918 (2007)

15. Tann D., et al.: Prospective study of serum homocysteine and risk of ischemic stroke among patients with pre-existing coronary heart disease. Stroke 34: 632-636 (2003)

16. Homocysreine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: JAMA 288: 2015-2022 (2002)

17. Suliman et al.: The reverse epidemiology of plasma total homocysteine as a mortality risk factor in retakes to the impact of wasting and inflammation. Nephrol. Dial. Transplant. 22: 203-217 (2007)

18. Barter P.J., Rye K.A.: Homocysteine and cardiovascular disease: is HDL the link? Circ. Res. 99: 565-566 (2006)

19. D-dimer local expression in increased in symptomatic patients undergoing carotid endarterectomy. Lancet 359: 228-231 (2004)

20. Elevated levels of inflammation, d-dimer and homo-cysteine are associated with adverse calf muscle characteristics and reduced calf strength in arterial disease. JAMA 279: 329-352 (2006)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr